Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9332718 | 0.98 | KDM4E (0.63) | KDM4EGAAESR1ESR2LMNA | |
| SCHEMBL8160950 | 0.84 | KDM4E (0.54) | KDM4EGAALMNAP4HTMCYP1A2 | |
| SCHEMBL1217437 | 0.76 | KDM4E (1.00) | KDM4EGAAESR1ESR2LMNA | |
| SCHEMBL145208 | 0.76 | KDM4E (0.91) | KDM4EGAAESR1ESR2LMNA | |
| SCHEMBL9336117 | 0.76 | ESR1 (0.46) | KDM4EGAAESR1ESR2TDP1 | |
| SCHEMBL8153468 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL22440642 | 0.74 | KDM4E (0.87) | KDM4EGAAESR1ESR2LMNA | |
| SCHEMBL5471362 | 0.74 | KDM4E (0.87) | KDM4EGAAESR1ESR2LMNA | |
| SCHEMBL31114652 | 0.74 | KDM4E (0.95) | KDM4EGAAESR1ESR2LMNA | |
| SCHEMBL28507747 | 0.74 | KDM4E (0.87) | KDM4EGAAESR1ESR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1876182-B1 | PHOSPHINE TRANSITION METAL COMPLEX, PROCESS FOR PRODUCING THE SAME AND ANTICANCER DRUG CONTAINING THE SAME | NIPPON CHEMICAL IND (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-8106186-B2 | Transition metal phosphine complex, method for producing same, and anticancer agent containing transition metal phospine complex | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090076267-A1 | TRANSITION METAL PHOSPHINE COMPLEX, METHOD FOR PRODUCING SAME, AND ANTICANCER AGENT CONTAINING TRANSITION METAL PHOSPINE COMPLEX | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1876182-A1 | PHOSPHINE TRANSITION METAL COMPLEX, PROCESS FOR PRODUCING THE SAME AND ANTICANCER DRUG CONTAINING THE SAME | Nippon Chemical Industrial Co., Ltd. (JP) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076267-A1 | TRANSITION METAL PHOSPHINE COMPLEX, METHOD FOR PRODUCING SAME, AND ANTICANCER AGENT CONTAINING TRANSITION METAL PHOSPINE COMPLEX | CDKL1, MASTL, AARS1 | KDM4E 3657/4885GAA 2569/4885ESR1 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.